World Journal of Surgery

, Volume 33, Issue 10, pp 2077–2081 | Cite as

Clinical and Pathologic Differences Between BRCA1-, BRCA2-, and Non-BRCA-Associated Breast Cancers in a Multiracial Developing Country

  • Cheng-Har Yip
  • N. A. Taib
  • W. Y. Choo
  • S. Rampal
  • M. K. Thong
  • S. H. Teo
Article

Abstract

Background

Mutations in BRCA1 and BRCA2 confer an increased risk to breast and other cancers, but to date there have only been limited numbers of studies of BRCA1- and BRCA2-associated cancers among Asians. Malaysia is a multiracial country with three main races: Malays, Chinese, Indians. We determined whether tumor pathologic features and clinical features differ in patients with and without BRCA mutations in this Asian population.

Methods

We conducted a retrospective review of the medical records of 152 women with breast cancer who underwent genetic testing for BRCA mutations. The patients self-reported ethnicity, age at onset, and clinical stage at diagnosis and tumor pathology were reviewed.

Results

A total of 31 patients carried germline deleterious mutations (16 BRCA1, 15 BRCA2). We found that tumors in BRCA1 carriers were more likely to be estrogen receptor (ER)-negative and progesterone receptor (PR)-negative. HER2 was more likely to be negative in both BRCA1 and BRCA2 subjects compared with non-BRCA subjects. We found a strong association between triple-negative status and BRCA1 carriers. In addition, tumors in BRCA1 carriers were more likely to be higher grade than those in BRCA2 and non-BRCA carriers; but the difference was not statistically significant.

Conclusions

These results suggest that tumors associated with BRCA1 mutations are distinct from those of BRCA2-associated and non-BRCA-associated breast cancers, and that the tumors associated with BRCA2 mutations are similar to the non-BRCA-associated breast cancers. Further studies are required to determine if the prognosis is different in each of these groups and the best management strategy for each group.

References

  1. 1.
    Yip CH, Taib NA, Mohamed I (2006) Epidemiology of breast cancer in Malaysia. Asian Pac J Cancer Prev 7:369–374PubMedGoogle Scholar
  2. 2.
    Minami Y, Tsubono Y, Nishino Y et al (2004) The increase of female breast cancer incidence in Japan: emergence of birth cohort effect. Int J Cancer 108:901–906PubMedCrossRefGoogle Scholar
  3. 3.
    Toh GT, Kang P, Lee SS et al (2008) BRCA1 and BRCA2 germline mutations in Malaysian women with early-onset breast cancer without a family history. PLoS ONE 3:e2024PubMedCrossRefGoogle Scholar
  4. 4.
    Thirthagiri E, Lee S, Kang P et al (2008) Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer. Breast Cancer Res 10:R59PubMedCrossRefGoogle Scholar
  5. 5.
    Purnomosari D, Pals G, Wahyono A et al (2007) BRCA1 and BRCA2 germline mutation analysis in the Indonesian population. Breast Cancer Res Treat 106:297–304PubMedCrossRefGoogle Scholar
  6. 6.
    Rashid MU, Zaidi A, Torres D et al (2006) Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients. Int J Cancer 119:2832–2839PubMedCrossRefGoogle Scholar
  7. 7.
    Song CG, Hu Z, Wu J et al (2006) The prevalence of BRCA1 and BRCA2 mutations in eastern Chinese women with breast cancer. J Cancer Res Clin Oncol 132:617–626PubMedCrossRefGoogle Scholar
  8. 8.
    Han SH, Lee KR, Lee DG et al (2006) Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer. Clin Genet 70:496–501PubMedCrossRefGoogle Scholar
  9. 9.
    Li WF, Hu Z, Rao NY et al (2008) The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat 110:99–109PubMedCrossRefGoogle Scholar
  10. 10.
    Karp SE, Tonin PN, Begin LR et al (1997) Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 80:435–441PubMedCrossRefGoogle Scholar
  11. 11.
    Atchley DP, Albarracin CT, Lopez A et al (2008) Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26:4282–4288PubMedCrossRefGoogle Scholar
  12. 12.
    Brekelmans CT, Seynaeve C, Menke-Pluymers M et al (2006) Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol 17:391–400PubMedCrossRefGoogle Scholar
  13. 13.
    Stoppa-Lyonnet D, Ansquer Y, Dreyfus H et al (2000) Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol 18:4053–4059PubMedGoogle Scholar
  14. 14.
    Rennert G, Bisland-Naggan S, Barnett-Griness O et al (2007) Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357:115–123PubMedCrossRefGoogle Scholar
  15. 15.
    Frank TS, Deffenbaugh AM, Reid JE et al (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10, 000 individuals. J Clin Oncol 20:1480–1490PubMedCrossRefGoogle Scholar
  16. 16.
    Rakha EA, Reis-Filho JS, Ellis IO (2008) Basal-like breast cancer: a critical review. J Clin Oncol 26:2568–2581PubMedCrossRefGoogle Scholar
  17. 17.
    Liu ZB, Liu GY, Yang WT et al (2008) Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients. Oncol Rep 20:987–994PubMedGoogle Scholar
  18. 18.
    Reis-Filho JS, Tutt AN (2008) Triple negative tumors: a critical review. Histopathology 52:108–118PubMedCrossRefGoogle Scholar
  19. 19.
    Cleator S, Heller W, Coombes RC (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8:235–244PubMedCrossRefGoogle Scholar
  20. 20.
    Musolino A, Michiara M, Bella MA et al (2005) Molecular profile and clinical variables in BRCA1-positive breast cancers: a population-based study. Tumori 91:505–512PubMedGoogle Scholar
  21. 21.
    Foulkes WD, Metcalfe K, Sun P et al (2004) Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 10:2029–2034PubMedCrossRefGoogle Scholar
  22. 22.
    James PA, Doherty R, Harris M et al (2006) Optimal selection of individuals for BRCA mutation testing: a comparison of available methods. J Clin Oncol 24:707–715PubMedCrossRefGoogle Scholar
  23. 23.
    Liede A, Malik IA, Aziz Z et al (2002) Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan. Am J Hum Genet 71:595–606PubMedCrossRefGoogle Scholar
  24. 24.
    Ang P, Lim IH, Lee TC et al (2007) BRCA1 and BRCA2 mutations in an Asian clinic-based population detected using a comprehensive strategy. Cancer Epidemiol Biomarkers Prev 16:2276–2284PubMedCrossRefGoogle Scholar
  25. 25.
    De Leon Matsuda ML, Liede A, Kwan E et al (2002) BRCA1 and BRCA2 mutations among breast cancer patients from the Philippines. Int J Cancer 98:596–603PubMedCrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2009

Authors and Affiliations

  • Cheng-Har Yip
    • 1
  • N. A. Taib
    • 1
  • W. Y. Choo
    • 2
  • S. Rampal
    • 2
  • M. K. Thong
    • 3
  • S. H. Teo
    • 4
  1. 1.Department of SurgeryUniversity Malaya Medical CentreKuala LumpurMalaysia
  2. 2.Department of Social and Preventive Medicine, Faculty of MedicineUniversity of MalayaKuala LumpurMalaysia
  3. 3.Genetics Unit, Department of PaediatricsUniversity Malaya Medical CentreKuala LumpurMalaysia
  4. 4.Cancer Research Initiatives Foundation, Sime Darby Medical CentreSubang JayaMalaysia

Personalised recommendations